Which Weight Management Treatment Suits Your Needs?
Ozempic vs Wegovy vs Mounjaro: Understanding the Key Differences
When comparing Ozempic vs Wegovy vs Mounjaro, it's essential to understand that these are distinct treatments with different licensed indications. Ozempic contains semaglutide but is licensed exclusively for type 2 diabetes management in the UK, making it inappropriate for weight management in non-diabetic patients. Wegovy, also containing semaglutide, is specifically licensed by the MHRA for weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities. Mounjaro (tirzepatide) represents a newer approach as a dual GIP and GLP-1 receptor agonist, also licensed for weight management with similar BMI criteria.
The fundamental distinction between Wegovy and Mounjaro lies in their mechanisms of action. Wegovy works as a single GLP-1 receptor agonist, mimicking the natural fullness hormone to reduce appetite and promote satiety after smaller meals. Mounjaro's dual action targets both GLP-1 and GIP receptors, potentially offering a different approach to appetite regulation and glucose metabolism. Both are prescription-only medicines that must be used alongside a reduced-calorie diet and increased physical activity, with clinical assessment required before treatment initiation.
Wegovy vs Mounjaro Pricing and Value Comparison
EverydayMeds offers transparent pricing for both Wegovy and Mounjaro, allowing patients and prescribers to make informed decisions without hidden costs. Wegovy starter doses begin at £79.99 for the 0.25mg pen (weeks 1-4), progressing through £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and reaching £209.99 for the 2.4mg maintenance dose. Our Getting Started bundles provide convenient dose progression options, such as the Intro Duo (0.25mg & 0.5mg) for £169.99 or the Progress Trio (0.5mg, 1mg & 1.7mg) for £369.99. New customers benefit from the FIRST40 discount code applied at checkout, whilst returning customers use DOSE25 for ongoing savings.
Mounjaro pricing follows a different structure due to its distinct dosing schedule, with comprehensive bundle options available for both treatments. The choice between Wegovy vs Mounjaro often comes down to individual response, tolerability, and prescriber recommendation rather than cost alone. Both treatments require the same rigorous clinical assessment process, with standard prescriber review taking 3 working days or express review available within 24 hours. EverydayMeds maintains the same high standards of cold-chain delivery and clinical oversight regardless of which treatment your prescriber recommends.
Clinical Evidence: STEP Trials and Treatment Outcomes
The clinical evidence supporting Wegovy comes primarily from the landmark STEP trial programme, with Wilding et al. (NEJM, 2021) demonstrating significant weight management outcomes. In the STEP 1 trial, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo. The STEP 5 trial showed sustained weight loss of approximately 15.2% at 2 years, whilst the SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major cardiovascular events.
When considering Ozempic vs Wegovy vs Mounjaro, it's important to note that direct head-to-head comparisons aren't available due to different trial designs and populations. Mounjaro's clinical evidence comes from separate trial programmes with different methodologies, making direct percentage comparisons inappropriate. Both Wegovy and Mounjaro have demonstrated efficacy in their respective clinical trials, but individual response varies significantly between patients, emphasising the importance of personalised prescriber assessment.
How Wegovy Works: GLP-1 Mechanism Explained
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of glucagon-like peptide-1, a natural hormone that regulates appetite and satiety. When administered via the weekly FlexTouch pen injection, semaglutide binds to GLP-1 receptors in the brain's appetite centres, promoting feelings of fullness and reducing food cravings. This mechanism helps patients feel satisfied with smaller portions whilst experiencing reduced appetite between meals. The treatment also slows gastric emptying, contributing to prolonged satiety after eating. Unlike oral appetite suppressants, Wegovy works through natural hormonal pathways, supporting sustainable eating pattern changes when combined with lifestyle modifications.
Streamlined Ordering Process for Both Treatments
EverydayMeds has simplified the process of accessing both Wegovy and Mounjaro through our comprehensive online platform. The journey begins with a 3-minute clinical assessment covering medical history, current medications, and weight management goals, ensuring appropriate treatment selection. Our qualified prescribers review each application within 3 working days (or 24 hours with express service), considering individual suitability for either Wegovy or Mounjaro based on clinical factors. Once approved, your prescription-only medicine is dispatched via next-day delivery using temperature-controlled cold-chain logistics to maintain product integrity. Our GPhC-registered pharmacy (#9012878) maintains rigorous quality standards throughout the entire process, from clinical assessment to doorstep delivery.
Storage and Practical Considerations
Storage requirements represent a key practical difference when comparing Wegovy vs Mounjaro for daily life management. Wegovy pens maintain their potency for up to 6 weeks at room temperature (below 30°C) once removed from refrigeration, offering superior travel flexibility compared to Mounjaro's 21-day room temperature limit. Both treatments require refrigeration at 2-8°C before first use and utilise pre-filled injection pens for convenient weekly administration. The dose escalation schedules differ between treatments, with Wegovy following a 5-step progression (0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg) over 16 weeks, whilst Mounjaro uses a 6-step escalation reaching higher maximum doses. These practical considerations often influence treatment choice alongside clinical factors, particularly for patients with active lifestyles or frequent travel requirements.
Dual Mechanism vs Single Agonist: Understanding the Science
The scientific distinction between Wegovy and Mounjaro extends beyond simple mechanism comparison to fundamental differences in hormonal pathway targeting. Wegovy's single GLP-1 receptor agonist action provides targeted appetite regulation through established pathways, with extensive real-world experience supporting its clinical profile. Mounjaro's innovative dual GIP and GLP-1 receptor agonist mechanism represents a newer approach, potentially offering different benefits for patients who require alternative hormonal pathway activation. Neither approach is inherently superior, as individual patient response varies significantly based on genetic factors, existing metabolism, and lifestyle variables.
When evaluating Ozempic vs Wegovy vs Mounjaro, the choice ultimately depends on individual clinical assessment rather than theoretical mechanism advantages. Both Wegovy and Mounjaro are available from EverydayMeds, allowing your prescriber to select the most appropriate option based on your specific medical profile, lifestyle requirements, and treatment goals. Our clinical team works closely with patients to monitor response and adjust treatment plans as needed, ensuring optimal outcomes regardless of which prescription-only medicine is initially selected.
Making Your Decision: Expert Support Available
EverydayMeds recognises that choosing between Wegovy and Mounjaro represents a significant healthcare decision requiring expert guidance and ongoing support. Our comprehensive approach includes detailed clinical assessment, prescriber consultation, and continuous monitoring throughout your weight management journey. Both treatments are available through our platform, with transparent pricing, genuine medications sourced directly from manufacturers, and professional clinical oversight at every step. Whether your prescriber recommends Wegovy's established GLP-1 action or Mounjaro's innovative dual mechanism, you'll receive the same high standard of care and support from our GPhC-registered team. Start your clinical assessment today using discount code FIRST40 for new customers or DOSE25 for returning patients, and discover which treatment option aligns with your individual needs and goals at https://everydaymeds.co.uk/collections/weight-loss.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
